AZD5363 at 0.4 or 2 µM suppressed growth in three of four LTED breast cancer cell lines over 5–10 days. HCC-1428/LTED remained unresponsive, showing that growth inhibition was model dependent. [1]
In HLF and HuH6 liver cancer cells, NEAT1v1 overexpression was associated with increased phospho-AKT and greater sensitivity to capivasertib in a 48-hour WST assay. The tested range was 25–400 µM, which limits conclusions about target specificity; the assay also does not distinguish growth arrest from cell death. [2]
AKT-pathway response in ER-positive LTED breast cancer cells
Cell-based study · MCF-7/LTED, ZR75-1/LTED, MDA-361/LTED and HCC-1428/LTED cells [1]
AZD5363 reduced downstream substrate phosphorylation while increasing AKT phosphorylation. Response varied among cell lines; phospho-AKT alone should not be treated as a readout of preserved catalytic activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 1, 2, 5, 10 and 15 µM (Figure 1A labels)
- Exposure duration
- 24 hours
- Method
- Immunoblotting after treatment in 10% dextran/charcoal-treated FBS
- Vehicle
- No-drug control; solvent identity/concentration not established from the read passages
- Reported limits
- No direct binding or isolated-enzyme assay in this experiment; replicate number for Figure 1A not specified in its caption.
Methods and source locations
Compound reported in the paper: Capivasertib (AZD5363); Compound label in the paper: AZD5363
Compound-level research findings only. No salt conversion, product-lot validation or clinical efficacy inference.
Figure 1A and caption; Results: Inhibition of AKT suppresses hormone-independent breast cancer cell growth; Methods: Cell lines; Immunoblot analysis and RTK arrays
Phosphorylation of PRAS40, GSK-3 and S6, with AKT phosphorylation at T308 and S473: Figure 1A includes actin, total S6 and phospho-AKT bands; no numerical band quantification adopted. — Figure 1A and caption; Results: Inhibition of AKT suppresses hormone-independent breast cancer cell growth; Methods: Cell lines; Immunoblot analysis and RTK arrays
Model-dependent growth inhibition in LTED breast cancer cells
Cell-based study · MCF-7/LTED, ZR75-1/LTED, MDA-361/LTED and HCC-1428/LTED cells [1]
Growth was suppressed in three of four LTED lines at concentrations ≤2 µM. HCC-1428/LTED was unresponsive under these conditions, despite the biochemical pathway effects seen in the companion signaling experiment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.4 or 2 µM AZD5363 versus no-drug control
- Exposure duration
- 5–10 days; media and drugs replenished every three days
- Method
- Triplicate cultures in 10% DCC-FBS; adherent cells counted with a Coulter Counter
- Vehicle
- No-drug control; solvent identity/concentration not established from read passages
- Reported limits
- Exact day for each line is not specified in Figure 1B; n=3 is preserved as reported rather than called independent biological replicates.
Methods and source locations
Compound reported in the paper: Capivasertib (AZD5363); Compound label in the paper: AZD5363
Compound-level research findings only. No salt conversion, product-lot validation or clinical efficacy inference.
Figure 1B and caption; Results: Inhibition of AKT suppresses hormone-independent breast cancer cell growth; Methods: Cell proliferation; Statistics
Adherent cell number relative to control in four LTED lines: Cell counting. Exact bar heights and IC50 values were not inferred from the image. — Figure 1B and caption; Results: Inhibition of AKT suppresses hormone-independent breast cancer cell growth; Methods: Cell proliferation; Statistics
NEAT1v1-associated capivasertib sensitivity in liver cancer cells
Cell-based study · HLF and HuH6 control cells versus stable NEAT1v1-overexpressing cells [2]
NEAT1v1-overexpressing cells showed increased phospho-AKT and greater loss of WST signal with capivasertib than control cells at several concentrations. This is a model-specific association, not proof of exclusive AKT-mediated cytotoxicity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 25, 50, 100, 200 and 400 µM capivasertib; DMSO control (0 µM)
- Exposure duration
- 48 hours of drug treatment
- Method
- Cell Counting Kit-8 WST viability assay; accompanying phospho-AKT immunoblot comparison
- Vehicle
- DMSO; each cell background normalized to its own DMSO control (100%)
- Reported limits
- DMSO percentage and product catalog/lot identity not established. Supplemental Table S1 was not retrieved. WST signal does not distinguish cytostasis from cell death.
Methods and source locations
Compound reported in the paper: Capivasertib (AZD5363); Compound label in the paper: capivasertib
Compound-level research findings only. No salt conversion, product-lot validation or clinical efficacy inference.
Figure 3C-D and caption; Results Section 3.3; Methods Sections 2.1, 2.3, 2.5 and 2.6
WST-derived viability in NEAT1v1-overexpressing versus control HLF and HuH6 cells: Figure 3D concentration labels read directly from viewed image; n and test from caption; SD semantics from Section 2.6. — Figure 3C-D and caption; Results Section 3.3; Methods Sections 2.1, 2.3, 2.5 and 2.6
Baseline phospho-AKT in NEAT1v1-overexpressing versus control cells: Figure 3C includes total AKT and GAPDH; no densitometry adopted. — Figure 3C-D and caption; Results Section 3.3; Methods Sections 2.1, 2.3, 2.5 and 2.6